BCL2 and early-onset autosomal dominant Alzheimer disease: MEL, through the upregulation of Bcl-2 expression and its antioxidant effects, may counteract neurodegeneration in Alzheimer’s disease, making it a promising candidate for further clinical investigation. These effects were observed at doses of 10 mg/kg/day administered orally in rats for 30 days—doses that translate to high equivalents in humans, falling within the neuroprotective rather than merely sleep-regulating range.